Regeneron Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Regeneron Pharmaceuticals Inc in the third quarter 2026?
Regeneron Pharmaceuticals Inc achieved a return on average equity (ROE) of 15.07 % in its third quarter 2026, which is below Regeneron Pharmaceuticals Inc 's average return on equity, which stands at 22.18%.

ROE has advanced compared to 13.81% in the second quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 39 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 993, from total ROE ranking in the second quarter 2026 at 1062.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	8.21 %	5.92 %	6.93 %	6.48 %	-
Y / Y Net Income Change	33.47 %	-6.81 %	-10.08 %	-7.97 %	8.91 %
Net Income (TTM) in Millions	4,817	4,329	4,423	4,505	4,578
Return On Equity (TTM)	15.07 %	13.81 %	14.32 %	14.83 %	15.31 %
REGN's Total Ranking	# 993	# 1062	# 885	# 880	# 871
Equity (TTM) in Millions	33,499	31,711	31,424	31,257	30,958
Seq. Equity Change	5.64 %	0.92 %	0.53 %	0.97 %	3.4 %
Seq. Net Income Change	50.26 %	78.34 %	-13.9 %	-42.15 %	4.92 %

Back to REGN Management Effectiveness >> REGN's 5 Years Annual ROE >> Compare REGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 40
Sector	# 107
Overall	# 993

Return On Equity Statistics
High	Average	Low
95.27 %	22.18 %	-46.44 %
(Dec 31 2012)		(Dec 31 2011)

REGN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	31,257	29,354	25,973	22,664	18,769
Y / Y Equity Change	6.48 %	13.02 %	14.6 %	20.75 %	70.23 %
Net Income in Millions	4,505	4,413	3,954	4,338	8,075
Y / Y Net Income Change	2.09 %	11.61 %	-8.87 %	-46.28 %	129.86 %
Return On Equity	14.41 %	15.03 %	15.22 %	19.14 %	43.03 %

Back to REGN Management Effectiveness >> REGN's 5 Years Annual ROE >> Compare REGN ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 14.41 %, despite net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
REGN's' Return on Equity at Yahoo Finance
REGN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for REGN's Competitors
Subscribers only: Roe for Regeneron Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for REGN's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %
West Pharmaceutical Services Inc	21.08 %
Brightspring Health Services Inc	20.31 %
Healthcare Services Group Inc	20.22 %
Vertex Pharmaceuticals Inc	20.08 %
Ge Healthcare Technologies Inc	20.04 %
Neurocrine Biosciences Inc	19.74 %
Ani Pharmaceuticals Inc	19.70 %
Johnson and Johnson	19.55 %
Beone Medicines Ltd	18.21 %

Date modified: 2026-10-31T17:28:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.